Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NASDAQ:CRSP NASDAQ:GPCR NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$122.52+3.2%$116.47$75.56▼$139.13$5.92B0.52479,342 shs648,324 shsCRSPCRISPR Therapeutics$74.92-2.4%$58.81$30.04▼$78.48$6.98B1.842.85 million shs2.67 million shsGPCRStructure Therapeutics$30.55+7.4%$21.49$13.22▼$42.57$1.64B-1.651.06 million shs1.21 million shsNUVLNuvalent$88.00+3.7%$78.78$55.53▼$106.32$6.12B1.3405,691 shs327,029 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+0.06%+0.12%-8.18%+7.21%+39.96%CRSPCRISPR Therapeutics+8.72%+16.05%+41.92%+30.14%+69.87%GPCRStructure Therapeutics+0.11%+9.25%+36.39%+50.53%-29.75%NUVLNuvalent+1.78%+2.76%+6.30%+3.40%-17.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$122.52+3.2%$116.47$75.56▼$139.13$5.92B0.52479,342 shs648,324 shsCRSPCRISPR Therapeutics$74.92-2.4%$58.81$30.04▼$78.48$6.98B1.842.85 million shs2.67 million shsGPCRStructure Therapeutics$30.55+7.4%$21.49$13.22▼$42.57$1.64B-1.651.06 million shs1.21 million shsNUVLNuvalent$88.00+3.7%$78.78$55.53▼$106.32$6.12B1.3405,691 shs327,029 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+0.06%+0.12%-8.18%+7.21%+39.96%CRSPCRISPR Therapeutics+8.72%+16.05%+41.92%+30.14%+69.87%GPCRStructure Therapeutics+0.11%+9.25%+36.39%+50.53%-29.75%NUVLNuvalent+1.78%+2.76%+6.30%+3.40%-17.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.00Buy$177.9345.23% UpsideCRSPCRISPR Therapeutics 2.42Hold$71.50-4.56% DownsideGPCRStructure Therapeutics 2.89Moderate Buy$68.67124.77% UpsideNUVLNuvalent 2.91Moderate Buy$118.8935.10% UpsideCurrent Analyst Ratings BreakdownLatest GPCR, CRSP, NUVL, and AXSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025AXSMAxsome TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CRSPCRISPR TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025GPCRStructure TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NUVLNuvalentWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/1/2025AXSMAxsome TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.009/30/2025AXSMAxsome TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.009/27/2025AXSMAxsome TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CRSPCRISPR TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GPCRStructure TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NUVLNuvalentWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/23/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.00(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$385.69M15.85N/AN/A$1.18 per share103.83CRSPCRISPR Therapeutics$37.31M182.63N/AN/A$22.64 per share3.31GPCRStructure TherapeuticsN/AN/AN/AN/A$15.10 per shareN/ANUVLNuvalentN/AN/AN/AN/A$14.99 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.07N/A43.45N/A-49.88%-283.22%-33.06%11/3/2025 (Estimated)CRSPCRISPR Therapeutics-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)GPCRStructure Therapeutics-$122.53M-$1.050.00N/AN/AN/A-21.31%-20.34%11/12/2025 (Estimated)NUVLNuvalent-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%11/11/2025 (Estimated)Latest GPCR, CRSP, NUVL, and AXSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025CRSPCRISPR Therapeutics-$1.32N/AN/AN/A$8.74 millionN/A11/3/2025Q3 2025AXSMAxsome Therapeutics-$0.80N/AN/AN/A$162.96 millionN/A8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/A8/6/2025Q2 2025GPCRStructure Therapeutics-$0.28-$0.36-$0.08-$0.36N/AN/A8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics1.661.571.51CRSPCRISPR TherapeuticsN/A16.6116.61GPCRStructure TherapeuticsN/A20.4820.48NUVLNuvalentN/A13.5713.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%CRSPCRISPR Therapeutics69.20%GPCRStructure Therapeutics91.78%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.30%CRSPCRISPR Therapeutics4.30%GPCRStructure Therapeutics5.60%NUVLNuvalent10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.90 million38.77 millionOptionableCRSPCRISPR Therapeutics46090.95 million87.04 millionOptionableGPCRStructure Therapeutics13657.60 million54.37 millionOptionableNUVLNuvalent4072.11 million64.75 millionOptionableGPCR, CRSP, NUVL, and AXSM HeadlinesRecent News About These CompaniesNuvalent, Inc. Stock (NUVL) Opinions on Cancer Therapy Developments and Insider SaleOctober 2, 2025 | quiverquant.comQNuvalent (NASDAQ:NUVL) CFO Sells $645,055.88 in StockOctober 2, 2025 | insidertrades.comNuvalent (NASDAQ:NUVL) CFO Alexandra Balcom Sells 7,588 SharesOctober 1, 2025 | marketbeat.comAlexandra Balcom Sells 20,000 Shares of Nuvalent (NASDAQ:NUVL) StockOctober 1, 2025 | marketbeat.comNuvalent, Inc. (NUVL) Presents at UBS Virtual Oncology Day TranscriptOctober 1, 2025 | seekingalpha.comNuvalent to Participate in the UBS 2025 Virtual Oncology DaySeptember 24, 2025 | prnewswire.com5,700 Shares in Nuvalent, Inc. $NUVL Acquired by Strs OhioSeptember 23, 2025 | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of "Buy" from AnalystsSeptember 23, 2025 | marketbeat.comNuvalent Completes New Drug Application SubmissionSeptember 22, 2025 | tipranks.comNuvalent (NASDAQ:NUVL) CEO Sells $2,135,160.00 in StockSeptember 18, 2025 | marketbeat.comJames Richard Porter Sells 27,000 Shares of Nuvalent (NASDAQ:NUVL) StockSeptember 18, 2025 | insidertrades.comVoya Investment Management LLC Has $8.53 Million Holdings in Nuvalent, Inc. $NUVLSeptember 18, 2025 | marketbeat.comNuvalent (NUVL): Assessing Valuation Following Subtle Shifts in Investor SentimentSeptember 17, 2025 | finance.yahoo.comNuvalent (NASDAQ:NUVL) Insider Henry Pelish Sells 3,725 SharesSeptember 14, 2025 | marketbeat.comNuvalent (NASDAQ:NUVL) Insider Sells $293,641.75 in StockSeptember 13, 2025 | insidertrades.com20,994 Shares in Nuvalent, Inc. $NUVL Bought by Voleon Capital Management LPSeptember 11, 2025 | marketbeat.comFred Alger Management LLC Cuts Stake in Nuvalent, Inc. $NUVLSeptember 11, 2025 | marketbeat.comNuvalent's (NUVL) Outperform Rating Reaffirmed at WedbushSeptember 10, 2025 | marketbeat.comPolar Asset Management Partners Inc. Reduces Stock Holdings in Nuvalent, Inc. $NUVLSeptember 9, 2025 | marketbeat.comNuvalent presents data from ARROS-1 trial of zidesamtinibSeptember 7, 2025 | msn.comNuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025September 7, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGPCR, CRSP, NUVL, and AXSM Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$122.52 +3.81 (+3.21%) Closing price 04:00 PM EasternExtended Trading$121.46 -1.06 (-0.87%) As of 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.CRISPR Therapeutics NASDAQ:CRSP$74.92 -1.86 (-2.42%) Closing price 04:00 PM EasternExtended Trading$75.61 +0.69 (+0.93%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Structure Therapeutics NASDAQ:GPCR$30.55 +2.10 (+7.38%) Closing price 04:00 PM EasternExtended Trading$30.50 -0.05 (-0.16%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Nuvalent NASDAQ:NUVL$88.00 +3.14 (+3.70%) Closing price 04:00 PM EasternExtended Trading$91.56 +3.56 (+4.05%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
